干眼症治疗市场（按产品形式、药物类型、最终用户、治疗时间和分销管道划分）—2025-2030 年全球预测

干眼症药物市场预计到 2024 年将达到 51.6 亿美元，到 2025 年将达到 54.9 亿美元，到 2030 年将达到 76.2 亿美元，复合年增长率为 6.72%。

主要市场统计数据
基准年2024年	51.6亿美元
预计2025年	54.9亿美元
预计2030年	76.2亿美元
复合年增长率（%）	6.72%

为全面的干眼症治疗奠定基础：技术进步和监管趋势凸显患者需求

近年来，受数位萤幕使用率上升、环境压力以及全球人口老化等因素的影响，干眼症的盛行率急剧上升。随着患者越来越多地寻求缓解眼睛不适，干眼症药物已成为医药创新和医疗保健投资的焦点。本介绍首先概述了干眼症的潜在风险因素，然后描绘了当前的生态系统，并强调了从睑板腺功能障碍到泪膜不稳定等多因素病因如何具有临床和商业重要性。

前所未有的创新和数位化整合将推动下一波干眼症治疗解决方案和市场变革

干眼症药物领域正在经历变革，重新定义治疗模式和市场结构。新型药物传递平台，例如微乳眼药水和缓释性眼内植入物，透过长期缓解眼部症状而无需频繁给药，彻底改变了患者的用药依从性。同时，从基于智慧型手机的泪液分析仪到远端监控平台等数位健康工具的整合，实现了即时患者数据收集，并促进了更个人化的治疗方法。

评估2025年美国关税对干眼症药物供应链的连锁反应：製造成本与全球贸易动态

2025年美国新关税的实施将给干眼症药物供应链带来巨大的成本压力。关键药用辅料和包装材料的关税正在推高製造成本，迫使企业重新评估筹资策略并协商替代供应商协议。因此，委託製造製造商面临利润压力，可能导致下游价格调整，进而影响患者用药管道和报销谈判。

深入研究各种细分领域，揭示治疗方式的人口统计和分布特征，以进行策略性资源配置

对市场区隔进行细緻的考察，可以揭示不同的患者和产品属性如何影响策略重点。虽然眼药水等剂型仍然是治疗方法的基石，但眼睑湿纸巾和眼膏等新兴产品可以满足需要针对性缓解（尤其是在睡眠和眼表清洁期间）的特殊患者的需求。凝胶和喷雾剂虽然市场定位较小，但为那些对传统眼药水不耐受或寻求快速缓解症状的患者提供了替代方案。

区域比较分析突显了美洲、欧洲、中东、非洲和亚太市场的驱动因素和挑战

区域动态对市场趋势有显着的影响，不同地区拥有不同的监管、经济和病患状况。在美洲，成熟的医疗基础设施和健全的报销机制支持优质製剂和创新给药系统的快速普及。临床医生和患者的高认知度推动了对先进疗法的需求，而支付方框架则对经过验证的临床效益和成本补偿进行奖励。

宣布创新伙伴关係、产品线策略和永续性承诺，确立干眼症治疗领域的竞争领导地位

主要企业正优先透过收购利基生物技术创新公司来扩展产品线，从而获得专有的免疫调节分子和先进的药物输送平台。其他公司则加强与合约研发机构的合作，以加速临床开发，同时优化资本配置。

干眼治疗公司推动创新的策略挑战：增强病人参与并确保供应链弹性

行业领导者应优先对下一代药物输送系统和新型治疗方法进行有针对性的研发投资，以满足不断变化的患者期​​望和报销标准。采用数位远端医疗整合技术，例如居家泪液评估和用于依从性追踪的远距医疗平台，可以实现产品差异化，并提高病人参与。

整合定性专业知识和定量检验的综合调查方法框架，用于干眼症市场分析

这项市场研究基于严谨、多层面的调查方法，旨在确保分析的深度和可靠性。主要研究包括对眼科医生、验光师和药物经济学专家等关键意见领袖的深入访谈，以提供有关临床使用和报销框架的真实观点。此外，与产业主管的直接对话也提供了关于策略重点、产品平臺和合作趋势的见解。

综合关注创新细分和区域差异动态的核心见解，以指导未来的策略决策

不断发展的干眼症药物市场的特点是技术创新的融合、不断变化的监管格局以及细緻入微的患者细分。先进製剂和数位医疗工具的引入有望重新定义护理标准，而关税驱动的供应链调整则凸显了营运敏捷性的重要性。按地区划分，市场成熟度各不相同，从美洲高度发展的报销体係到亚太地区成本敏感型成长市场，再到欧洲、中东和非洲地区复杂的法规。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

• 病人安全问题和监管指南正在推动无防腐剂人工泪液的广泛采用
• 增加新型眼科缓释给药系统的投资
• 利菲特作为第一线治疗药物的出现改变了全球干眼症的治疗通讯协定
• 干眼护理中非处方笺缓解药物的需求不断增加
• 个人化干眼症管理和远端患者监护的数位诊断快速成长
• 由于具有成本效益的生物替代品的出现，针对泪膜稳态的生物相似药开发激增
• 监管要求和患者偏好正在推动全球转向不含防腐剂的人工泪液
• 个人化数位诊断在远端监控和客製化干眼症护理途径中越来越受欢迎。
• 全球投资激增，推动干眼症药物生产
• 创新药物传输系统改善干眼症治疗效果

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：干眼症治疗市场（依产品类型）

• 眼药水
• 眼睑擦拭巾
• 凝胶和软膏
• 喷

第九章：干眼症治疗市场（依药物类型）

• 非处方药
• 处方药

第 10 章 干眼症治疗市场（依药物类型）

• 抗发炎药物
• 人工泪液
• 免疫调节药物
• 脂质治疗

第 11 章 干眼症治疗市场（依最终使用者划分）

• 成人
• 老年人
• 孩子们

第十二章 干眼症治疗市场（依治疗期）

• 长期
• 短期

第十三章 干眼症治疗市场（依通路）

• 离线
  • 医院和诊所
  • 零售药局
  • 专科诊所
• 在线的

14.美洲干眼症治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 欧洲、中东和非洲干眼症治疗市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16. 亚太干眼症治疗市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Kiora Pharmaceuticals, Inc.
  • Harrow Health, Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratorios Sophia SA De CV
  • Nicox SA
  • Ocugen, Inc.
  • Viatris Inc.
  • Ocular Therapeutix, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Wockhardt Ltd.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Dry Eye Medication Market was valued at USD 5.16 billion in 2024 and is projected to grow to USD 5.49 billion in 2025, with a CAGR of 6.72%, reaching USD 7.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 5.16 billion
Estimated Year [2025]	USD 5.49 billion
Forecast Year [2030]	USD 7.62 billion
CAGR (%)	6.72%

Setting the Stage for a Comprehensive Dry Eye Medication Overview Highlighting Patient Needs Technological Advances and Regulatory Dynamics

The prevalence of dry eye disease has surged in recent years, propelled by increased digital screen usage, environmental stressors, and an aging global population. As patients increasingly seek relief from ocular discomfort, the dry eye medication landscape has become a focal point for pharmaceutical innovation and healthcare investment. Beginning with a broad understanding of underlying risk factors, this introduction maps out the current ecosystem, highlighting how multifactorial etiologies-from meibomian gland dysfunction to tear film instability-drive both clinical and commercial imperatives.

Moreover, emerging regulatory standards and patient expectations are reshaping product development priorities. With regulatory bodies emphasizing safety, efficacy, and patient-centric outcomes, manufacturers are navigating a complex framework that balances innovation with compliance. At the same time, healthcare providers are adopting minimally invasive treatment protocols, while payers demand evidence of cost-effectiveness and quality-of-life improvements. Against this backdrop, stakeholders must align strategic objectives with patient needs, ensuring that portfolios address acute symptoms and long-term ocular surface health.

In sum, this introduction sets the stage for a deeper exploration of market forces, technological breakthroughs, and policy dynamics that collectively influence the trajectory of dry eye therapies. It underscores the importance of a holistic perspective-one that integrates clinical science, commercial strategy, and patient experience-to capitalize on growth opportunities in a rapidly evolving arena.

Unprecedented Innovations and Digital Integration Driving the Next Wave of Dry Eye Therapeutic Solutions and Market Evolution

The dry eye medication landscape is witnessing transformative shifts that redefine therapeutic paradigms and market structures. Novel drug delivery platforms, such as microemulsion-based eye drops and sustained-release ocular inserts, are revolutionizing patient adherence by offering extended relief without frequent administration. Concurrently, the integration of digital health tools-ranging from smartphone-based tear film analyzers to remote monitoring platforms-enables real-time patient data collection, fostering more personalized treatment regimens.

At the same time, advancements in immunomodulatory agents are unlocking new pathways for chronic inflammation management, while lipid-based therapies are gaining traction for their capacity to restore tear film integrity. These innovations are complemented by a growing emphasis on preservative-free formulations, addressing safety concerns tied to long-term ocular surface exposure. In parallel, strategic collaborations between biotech firms and academic institutions are accelerating the translation of cutting-edge research into market-ready assets.

Meanwhile, evolving reimbursement frameworks are prompting manufacturers to demonstrate robust clinical and economic benefits, thereby influencing development timelines and go-to-market tactics. As a result, stakeholders are prioritizing real-world evidence generation and value-based contracting to secure favorable coverage decisions. Taken together, these converging forces herald a new era of patient-centric, data-driven dry eye therapeutics that promise enhanced efficacy, safety, and accessibility.

Assessing the Ripple Effects of 2025 United States Tariffs on Dry Eye Medication Supply Chains Manufacturing Costs and Global Trade Dynamics

In 2025, the implementation of new United States tariffs has introduced significant cost pressures across the dry eye medication supply chain. Tariffs on key pharmaceutical excipients and packaging materials have elevated manufacturing expenses, compelling companies to reassess sourcing strategies and negotiate alternative supplier agreements. Consequently, contract manufacturers are experiencing margin squeezes, leading to potential price adjustments downstream that may affect patient access and reimbursement negotiations.

In response, some firms are relocating production to tariff-exempt regions or investing in vertical integration to mitigate external cost volatility. These strategic shifts are accompanied by intensified risk management protocols, including dual-sourcing policies and inventory buffering, to ensure product availability amid fluctuating trade dynamics. Moreover, regulatory filings are now incorporating tariff impact assessments, reflecting a more comprehensive approach to product cost modeling.

As trade tensions evolve, market participants are also exploring local manufacturing incentives and government partnerships aimed at enhancing domestic production capacity. While such initiatives may bolster supply resilience, they require significant capital outlays and lead times. Ultimately, understanding the cumulative effects of tariff-related disruptions is critical for stakeholders intent on balancing cost containment, supply continuity, and patient affordability in a highly competitive marketplace.

Deep Dive into Diverse Segmentation Dimensions Illuminating Treatment Modalities Demographics and Distribution Nuances for Strategic Resource Allocation

A nuanced examination of market segmentation reveals how different patient and product attributes shape strategic priorities. Formulations such as eye drops remain the cornerstone of treatment regimens, but emerging options like eyelid wipes and ointments cater to specialized patient needs, particularly those requiring targeted relief during sleep or for ocular surface hygiene. Gels and sprays, though niche, offer alternatives for individuals intolerant to conventional drop instillation or seeking rapid symptomatic relief.

Diverging between over-the-counter availability and prescription-only therapies, manufacturers must tailor their promotional and distribution strategies accordingly. While artificial tears and anti-inflammatory medications dominate the retail shelf, immunomodulatory agents and lipid-based therapies occupy prescription channels, reflecting higher clinical complexity and oversight. Furthermore, the age-based segmentation of adults, geriatrics, and pediatrics underscores varying compliance challenges and dosing considerations, demanding bespoke educational and packaging features.

Treatment duration further refines the marketplace, with short-term interventions addressing acute flare-ups and long-term regimens focusing on chronic management. Finally, distribution channels-from hospital clinics and specialty centers to retail pharmacies and digital storefronts-determine outreach effectiveness and patient convenience. Offline channels benefit from clinical endorsements, whereas online platforms excel in convenience and broader geographic reach. Collectively, these segmentation dimensions illuminate nuanced growth pockets and inform targeted resource allocation across the product lifecycle.

Comparative Regional Analysis Revealing Distinct Drivers Opportunities and Challenges Spanning Americas EMEA and Asia Pacific Markets

Regional dynamics exert a profound influence on market trajectories, with each geography presenting distinct regulatory, economic, and patient profile considerations. In the Americas, mature healthcare infrastructure and robust reimbursement mechanisms support rapid adoption of premium formulations and innovative delivery systems. High awareness levels among clinicians and patients drive demand for advanced therapies, while payer frameworks reward demonstrable clinical benefits and cost-offsets.

Conversely, the Europe, Middle East & Africa region exhibits heterogeneity in regulatory pathways and economic maturity. Western European markets emphasize stringent safety and real-world evidence requirements, whereas emerging markets in the Middle East and Africa prioritize affordability and access. Navigating variable import regulations and localized pricing controls remains a key strategic focus, as does forging partnerships with regional distributors to streamline market entry.

In Asia-Pacific, rising dry eye prevalence is fueled by urbanization, pollution, and digital device proliferation. While developed markets like Japan and Australia show eagerness for next-generation therapies, cost-sensitive markets in Southeast Asia necessitate tiered pricing models and localized manufacturing alliances. Digital health adoption, particularly tele-ophthalmology platforms, is accelerating in populous markets, offering novel avenues for patient engagement and post-market support. These regional insights underscore the necessity of differentiated market strategies aligned with local healthcare dynamics.

Unveiling Innovative Partnerships Pipeline Strategies and Sustainability Initiatives Defining Competitive Leadership in Dry Eye Therapeutics

Leading companies in the dry eye medication arena are distinguished by their strategic investment in R&D, global expansion plans, and portfolio diversification. Some industry frontrunners have prioritized pipeline enrichment through acquisitions of niche biotech innovators, gaining access to proprietary immunomodulatory molecules and advanced drug delivery platforms. Others have cemented alliances with contract research organizations to expedite clinical development while optimizing capital deployment.

Simultaneously, partnerships with digital health startups are enabling select players to integrate remote monitoring solutions and personalized dosing algorithms into their offerings. Geographic expansion remains a critical theme, with firms establishing regional hubs to navigate local regulatory landscapes and bolster distribution networks. Collaboration with specialist eye clinics and ophthalmology societies further amplifies thought leadership and accelerates market penetration for cutting-edge therapies.

Furthermore, companies are increasingly focusing on sustainability and corporate responsibility, implementing eco-friendly packaging and reducing carbon footprints across manufacturing operations. Such initiatives not only resonate with stakeholder expectations but also align with emerging regulatory mandates. Overall, the competitive landscape is characterized by dynamic collaborations, technological convergence, and a relentless drive to deliver differentiated patient value.

Strategic Imperatives for Dry Eye Medication Companies to Drive Innovation Enhance Patient Engagement and Ensure Supply Chain Resilience

Industry leaders should prioritize targeted R&D investments in next-generation drug delivery systems and novel therapeutic modalities to meet evolving patient expectations and reimbursement criteria. Embracing digital health integration, including telemedicine platforms for home-based tear film assessments and adherence tracking, will differentiate offerings and foster stronger patient engagement.

Simultaneously, firms must fortify supply chain resilience by diversifying supplier portfolios and exploring localized manufacturing partnerships to mitigate tariff-induced cost fluctuations. Cultivating collaborative relationships with healthcare providers and payers through value-based contracting will support favorable formulary positioning and secure long-term revenue streams.

Moreover, adopting flexible pricing models that reflect regional economic conditions and patient affordability can unlock underserved markets, particularly in Asia-Pacific and parts of EMEA. Companies should also enhance educational outreach, leveraging digital channels and patient-support programs to elevate disease awareness and drive early intervention. By aligning product innovation, market access strategies, and operational agility, industry leaders can capitalize on emerging opportunities while mitigating potential risks in a competitive and regulatory-intensive environment.

Comprehensive Methodological Framework Integrating Qualitative Expertise and Quantitative Validation for Dry Eye Market Analysis

This market study is founded on a rigorous, multi-pronged research methodology designed to ensure analytical depth and reliability. Primary research efforts included in-depth interviews with key opinion leaders spanning ophthalmologists, optometrists, and pharmacoeconomics experts, providing real-world perspectives on clinical usage and reimbursement frameworks. Additionally, direct consultations with industry executives yielded insights into strategic priorities, product pipelines, and partnership trends.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, company annual reports, and industry white papers. Data triangulation techniques were employed to reconcile divergent information sources, while advanced statistical tools facilitated validation of qualitative findings against quantitative datasets. Segment-specific analyses were conducted via cross-tabulation of product form, drug type, medication classification, end-user demographics, treatment duration, and distribution channel variables.

Furthermore, region-specific regulatory and tariff impact assessments were integrated to contextualize market dynamics across the Americas, EMEA, and Asia-Pacific. All research outputs underwent rigorous peer review to ensure consistency, accuracy, and adherence to ethical research standards. This comprehensive approach underpins the study's actionable insights and strategic recommendations.

Synthesis of Core Findings Emphasizing Innovation Segmentation Dynamics and Regional Variances Guiding Future Strategic Decisions

The evolving dry eye medication market is characterized by a convergence of technological innovation, shifting regulatory landscapes, and nuanced patient segmentation. The introduction of advanced formulations and digital health tools promises to redefine therapeutic standards, while tariff-induced supply chain adjustments underscore the importance of operational agility. Regionally, market maturity varies from highly developed reimbursement systems in the Americas to cost-sensitive growth arenas in Asia-Pacific and regulatory complexities across EMEA.

Strategic segmentation analysis highlights the critical balance between over-the-counter accessibility and prescription-grade efficacy, as well as the imperative for tailored approaches across diverse age groups and treatment durations. Competitive dynamics are increasingly shaped by mergers and acquisitions, digital partnerships, and sustainability initiatives, reflecting a holistic value proposition that extends beyond pharmacology.

In conclusion, stakeholders that align their strategic investments with emerging trends-prioritizing innovation, patient-centricity, and supply chain resilience-will be best positioned to capture value in this rapidly transforming landscape. The insights offered herein provide a foundation for informed decision-making and long-term competitive advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Expansion of preservative-free artificial tears driven by patient safety concerns and regulatory guidance
• 5.2. Rising investment in novel ocular drug delivery systems for sustained release formulations
• 5.3. Emergence of lifitegrast as a first-line therapy reshaping dry eye treatment protocols globally
• 5.4. Growing demand for prescription free relief in dry eye care
• 5.5. Rapid growth of digital diagnostics for personalized dry eye management and remote patient monitoring
• 5.6. Surge in biosimilar development targeting tear film homeostasis with cost-effective biologic alternatives
• 5.7. Regulatory mandates and patient preferences drive global shift toward preservative-free artificial tears
• 5.8. Personalized digital diagnostics gain traction for remote monitoring and tailored dry eye care pathways
• 5.9. Surging investments to advance the production of dry eye medications globally
• 5.10. Innovative drug delivery systems to improve dry eye treatment outcomes

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Dry Eye Medication Market, by Product Form

• 8.1. Introduction
• 8.2. Eye Drops
• 8.3. Eyelid Wipes
• 8.4. Gels & Ointments
• 8.5. Sprays

9. Dry Eye Medication Market, by Drug Type

• 9.1. Introduction
• 9.2. Over-The-Counter Medication
• 9.3. Prescription Medication

10. Dry Eye Medication Market, by Medication Type

• 10.1. Introduction
• 10.2. Anti-inflammatory Medications
• 10.3. Artificial Tears
• 10.4. Immunomodulatory Agents
• 10.5. Lipids-Based Therapy

11. Dry Eye Medication Market, by End-user

• 11.1. Introduction
• 11.2. Adults
• 11.3. Geriatrics
• 11.4. Pediatrics

12. Dry Eye Medication Market, by Treatment Duration

• 12.1. Introduction
• 12.2. Long Term
• 12.3. Short Term

13. Dry Eye Medication Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Offline
  • 13.2.1. Hospitals & Clinics
  • 13.2.2. Retail Pharmacies
  • 13.2.3. Specialty Clinics
• 13.3. Online

14. Americas Dry Eye Medication Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Dry Eye Medication Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Dry Eye Medication Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. Alcon Inc.
  • 17.3.3. Bausch + Lomb Corporation
  • 17.3.4. Kiora Pharmaceuticals, Inc.
  • 17.3.5. Harrow Health, Inc.
  • 17.3.6. Johnson & Johnson Services, Inc.
  • 17.3.7. Laboratorios Sophia S.A. De C.V.
  • 17.3.8. Nicox S.A.
  • 17.3.9. Ocugen, Inc.
  • 17.3.10. Viatris Inc.
  • 17.3.11. Ocular Therapeutix, Inc.
  • 17.3.12. Otsuka Pharmaceutical Co., Ltd.
  • 17.3.13. Santen Pharmaceutical Co., Ltd.
  • 17.3.14. Wockhardt Ltd.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. DRY EYE MEDICATION MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. DRY EYE MEDICATION MARKET: RESEARCHAI
• FIGURE 28. DRY EYE MEDICATION MARKET: RESEARCHSTATISTICS
• FIGURE 29. DRY EYE MEDICATION MARKET: RESEARCHCONTACTS
• FIGURE 30. DRY EYE MEDICATION MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. DRY EYE MEDICATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYELID WIPES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ARTIFICIAL TEARS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIPIDS-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LONG TERM, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SHORT TERM, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 64. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 65. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 66. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 67. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 68. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 69. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 70. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 71. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 72. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 73. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 75. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 77. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 79. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 80. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 81. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 82. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 83. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 84. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 85. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 86. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 87. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 88. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 89. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 90. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 91. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 92. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 93. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 94. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 95. CANADA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 96. CANADA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 97. CANADA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 98. CANADA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 99. CANADA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 100. CANADA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 101. CANADA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 102. CANADA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 103. CANADA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 104. CANADA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 105. CANADA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 106. CANADA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 107. CANADA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 108. CANADA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 109. MEXICO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 110. MEXICO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 111. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 112. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 113. MEXICO DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 114. MEXICO DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 115. MEXICO DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 116. MEXICO DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 117. MEXICO DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 118. MEXICO DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 119. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 120. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 121. MEXICO DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 122. MEXICO DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 123. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 124. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 125. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 126. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 127. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 128. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 129. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 130. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 131. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 132. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 133. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 134. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 135. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 136. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 137. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 138. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 139. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 140. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 141. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 142. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 143. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 144. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 145. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 146. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 147. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 148. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 149. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 150. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 167. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 168. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 169. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 170. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 171. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 172. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 173. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 174. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 175. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 176. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 177. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 178. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 179. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 180. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 181. GERMANY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 182. GERMANY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 183. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 184. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 185. GERMANY DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 186. GERMANY DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 187. GERMANY DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 188. GERMANY DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 189. GERMANY DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 190. GERMANY DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 191. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 192. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 193. GERMANY DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 194. GERMANY DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 195. FRANCE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 196. FRANCE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 197. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 198. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 199. FRANCE DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 200. FRANCE DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 201. FRANCE DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 202. FRANCE DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 203. FRANCE DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 204. FRANCE DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 205. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 207. FRANCE DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 208. FRANCE DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 209. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 210. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 211. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 212. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 213. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 214. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 215. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 216. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 217. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 218. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 219. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 221. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 222. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 223. ITALY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 224. ITALY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 225. ITALY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 226. ITALY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 227. ITALY DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 228. ITALY DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 229. ITALY DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 230. ITALY DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 231. ITALY DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 232. ITALY DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 233. ITALY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 234. ITALY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 235. ITALY DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 236. ITALY DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 237. SPAIN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 238. SPAIN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 239. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 240. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 241. SPAIN DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 242. SPAIN DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 243. SPAIN DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 244. SPAIN DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 245. SPAIN DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 246. SPAIN DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 247. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 249. SPAIN DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 250. SPAIN DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 251. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 252. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 253. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 254. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 255. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 256. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 257. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 258. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 259. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 260. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 261. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 262. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 263. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 264. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 265. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 266. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 267. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 268. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 270. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 272. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 274. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 276. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 278. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 280. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 282. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 284. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 286. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 287. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 288. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 289. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 291. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 292. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 293. DENMARK DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 294. DENMARK DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 295. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 296. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 297. DENMARK DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 298. DENMARK DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 299. DENMARK DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 300. DENMARK DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 301. DENMARK DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 302. DENMARK DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 303. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 304. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 305. DENMARK DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 306. DENMARK DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 307. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 308. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 309. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 310. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 311. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 312. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 313. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 314. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 315. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 316. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 317. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 318. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 319. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 320. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 321. QATAR DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 322. QATAR DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 323. QATAR DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 324. QATAR DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 325. QATAR DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 326. QATAR DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 327. QATAR DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 328. QATAR DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 329. QATAR DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
• TABLE 330. QATAR DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
• TABLE 331. QATAR DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. QATAR DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 333. QATAR DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 334. QATAR DRY EYE MEDICATION MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 335. FINLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 336. FINLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 337. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 338. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 339. FINLAND DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2018-2024 (USD MILLION)
• TABLE 340. FINLAND DRY EYE MEDICATION MARKET SIZE, BY MEDICATION TYPE, 2025-2030 (USD MILLION)
• TABLE 341. FINLAND DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 342. FINLAND DRY EYE MEDICATION MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 343. FINLAND DRY EYE MEDICATION MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MI